IMPACT OF ROUX-EN-Y GASTRIC BYPASS SURGERY (RYGB) ON METABOLIC SYNDROME COMPONENTS AND ON THE USE OF ASSOCIATED DRUGS IN OBESE PATIENTS

ABSTRACT – Background – The prevalence of obesity and metabolic syndrome is increasing worldwide and both behavior modification and drug ther-apy have low adherence. Gastric bypass has shown effective results in both reducing weight and improving comorbidities. Objective – To evaluate the impact of Roux-en-Y Gastric Bypass Surgery (RYGB) on both metabolic syndrome components and the use of associated drugs in obese patients. Methods – Historical cohort of patients subjected to Roux-en-Y Gastric Bypass Surgery (RYGB) between January 2007 and March 2014 in a private clinic. The sample consisted of 273 obese class II and III individuals, 86.4% of whom were female, with age ≥20 years, followed up for 2 months after surgery. Sociodemographic, anthropometric, biochemical, clinical, and drug-use data were collected from patients’ medical records. Results – Significant differences were found in weight, body mass index and waist circumference, after 60 postoperative days. Components for metabolic syndrome diag-nosis (hypertension